RxDoctor Payments Data

Kavitha Sravanthi Kadumpalli, MD

Pulmonary Disease · Raleigh, NCNPI 1417000456

Payments from drug & device makers

$465in general payments, 2019–2025

Across 24 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$98
  • Philips North America LLC$90
  • Grifols USA, LLC$44
  • AstraZeneca$43
  • Sanofi$42
  • Mylan Specialty L.p.$35
  • plus $113 from 5 others

What the payments were for

  • Food & beverage$41489%
  • Education$5111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$465 in reported general payments places this provider in the 30th percentile of 393 pulmonary disease providers in North Carolina.

See all pulmonary disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$94,550
Medicare patients
699
Services billed
1,572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter755$635,486
Breo ElliptaFluticasone/Vilanterol319$150,578
Dupixent PenDupilumab25$101,614
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr184$98,224
Spiriva RespimatTiotropium Bromide135$83,901
Stiolto RespimatTiotropium Br/Olodaterol Hcl118$78,575
Breztri AerosphereBudesonide/Glycopyr/Formoterol68$54,571
Arnuity ElliptaFluticasone Furoate168$42,351
SymbicortBudesonide/Formoterol Fumarate110$33,433
Spiriva HandihalerTiotropium Bromide21$23,708
Advair HfaFluticasone Propion/Salmeterol50$22,619
Incruse ElliptaUmeclidinium Bromide39$17,935
Albuterol Sulfate HfaAlbuterol Sulfate520$14,617
Pirfenidone18$12,439
Fluticasone-SalmeterolFluticasone Propion/Salmeterol47$8,483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$98$944,5741,465 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$43$96,169198 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 393 pulmonary disease providers in North Carolina.

Other pulmonary disease in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →